Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.3 BC Cancer Agency VIC Cancer Info Ctr | On Loan, due Wednesday, March 20, 2024 | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
Ten years after his leukemia diagnosis, Ryan is a survivor who is reluctant to take risks and move forward with his life. The opportunity to take a backpacking trip through the Andes Mountains changes him and his perception of his cancer experience from one of Survivor to Thriver.
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
Table of Contents:; Introduction; Here to help; Your child - the initial diagnosis; Your child - coping with change; Parents - coming to terms with your feelings; Siblings - helping them cope too; Communicating with your extended family and friends; The new normal; More information
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
"Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia…